4.44
0.03 (0.68%)
| Previous Close | 4.41 |
| Open | 4.41 |
| Volume | 243,485 |
| Avg. Volume (3M) | 547,709 |
| Market Cap | 258,806,720 |
| Price / Earnings (Forward) | 30.30 |
| Price / Sales | 1.53 |
| Price / Book | 0.520 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -6.00% |
| Operating Margin (TTM) | -20.10% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 9.60% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 4.68 |
| Operating Cash Flow (TTM) | -5.14 M |
| Levered Free Cash Flow (TTM) | -107.66 M |
| Return on Assets (TTM) | -3.14% |
| Return on Equity (TTM) | -2.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vanda Pharmaceuticals Inc. | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.16% |
| % Held by Institutions | 77.05% |
| 52 Weeks Range | ||
| Median | 13.00 (192.79%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 01 Aug 2024 | 13.00 (192.79%) | Buy | 5.64 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Oct 2024 | Announcement | Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share |
| 14 Oct 2024 | Announcement | Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. |
| 19 Sep 2024 | Announcement | FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis |
| 11 Sep 2024 | Announcement | Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference |
| 04 Sep 2024 | Announcement | Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference |
| 29 Aug 2024 | Announcement | Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference |
| 31 Jul 2024 | Announcement | Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results |
| 26 Jul 2024 | Announcement | Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |